FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2986351352> ?p ?o ?g. }

• W2986351352 endingPage "215" @default.
• W2986351352 startingPage "215" @default.
• W2986351352 abstract "Importance Basket-design clinical trials that allow investigation of treatment effects on different clinical syndromes that share the same molecular pathophysiology have not previously been attempted in neurodegenerative disease. Objective To assess the safety, tolerability, and pharmacodynamics of the microtubule stabilizer TPI-287 (abeotaxane) in Alzheimer disease (AD) or the 4-repeat tauopathies (4RT) progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). Design, Setting, and Participants Two parallel-design, double-blind, placebo-controlled phase 1 randomized clinical trials in AD and 4RT were conducted from December 20, 2013, through May 4, 2017, at the University of California, San Francisco, and University of Alabama at Birmingham. A total of 94 patients with clinically diagnosed AD (n = 39) and 4RT (n = 55) were screened; of these, 3 refused to participate, and 10 with AD and 11 with 4RT did not meet inclusion criteria. A total of 29 patients with AD, 14 with PSP, and 30 with β-amyloid–negative CBS (determined on positron emission tomography findings) were enrolled. Data were analyzed from December 20, 2013, through May 4, 2017, based on modified intention to treat. Interventions Randomization was 8:3 drug to placebo in 3 sequential dose cohorts receiving 2.0, 6.3, or 20.0 mg/m2of intravenous TPI-287 once every 3 weeks for 9 weeks, with an optional 6-week open-label extension. Main Outcomes and Measures Primary end points were safety and tolerability (maximal tolerated dose) of TPI-287. Secondary and exploratory end points included TPI-287 levels in cerebrospinal fluid (CSF) and changes on biomarker, clinical, and neuropsychology measures. Results A total of 68 participants (38 men [56%]; median age, 65 [range, 50-85] years) were included in the modified intention-to-treat analysis, of whom 26 had AD (14 women [54%]; median age, 63 [range, 50-76] years), and 42 had 4RT (16 women [38%]; median age, 69 [range, 54-83] years). Three severe anaphylactoid reactions occurred in TPI-287–treated patients with AD, whereas none were seen in patients with 4RT, leading to a maximal tolerated dose of 6.3 mg/m2for AD and 20.0 mg/m2for 4RT. More falls (3 in the placebo group vs 11 in the TPI-287 group) and a dose-related worsening of dementia symptoms (mean [SD] in the CDR plus NACC FTLD-SB [Clinical Dementia Rating scale sum of boxes with frontotemporal dementia measures], 0.5 [1.8] in the placebo group vs 0.7 [1.6] in the TPI-287 group; median difference, 1.5 [95% CI, 0-2.5];P = .03) were seen in patients with 4RT. Despite undetectable TPI-287 levels in CSF, CSF biomarkers demonstrated decreased chitinase-3–like protein-1 (YKL-40) levels in the 4RT treatment arm (mean [SD], −8.4 [26.0] ng/mL) compared with placebo (mean [SD], 10.4 [42.3] ng/mL; median difference, −14.6 [95% CI, −30.0 to 0.2] ng/mL;P = .048, Mann-Whitney test). Conclusions and Relevance In this randomized clinical trial, TPI-287 was less tolerated in patients with AD than in those with 4RT owing to the presence of anaphylactoid reactions. The ability to reveal different tau therapeutic effects in various tauopathy syndromes suggests that basket trials are a valuable approach to tau therapeutic early clinical development. Trial Registration ClinicalTrials.gov identifiers:NCT019666666andNCT02133846" @default.
• W2986351352 created "2019-11-22" @default.
• W2986351352 creator A5000251461 @default.
• W2986351352 creator A5004309716 @default.
• W2986351352 creator A5010100808 @default.
• W2986351352 creator A5013396563 @default.
• W2986351352 creator A5013736647 @default.
• W2986351352 creator A5014895236 @default.
• W2986351352 creator A5019555711 @default.
• W2986351352 creator A5024865877 @default.
• W2986351352 creator A5025837253 @default.
• W2986351352 creator A5026319863 @default.
• W2986351352 creator A5026607111 @default.
• W2986351352 creator A5029927430 @default.
• W2986351352 creator A5037972521 @default.
• W2986351352 creator A5042845698 @default.
• W2986351352 creator A5046120768 @default.
• W2986351352 creator A5049403885 @default.
• W2986351352 creator A5052536571 @default.
• W2986351352 creator A5055043813 @default.
• W2986351352 creator A5056503861 @default.
• W2986351352 creator A5059104887 @default.
• W2986351352 creator A5060811086 @default.
• W2986351352 creator A5063637830 @default.
• W2986351352 creator A5072009949 @default.
• W2986351352 creator A5075757950 @default.
• W2986351352 creator A5090742144 @default.
• W2986351352 date "2020-02-01" @default.
• W2986351352 modified "2023-10-15" @default.
• W2986351352 title "Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome" @default.
• W2986351352 cites W1906424257 @default.
• W2986351352 cites W1953027527 @default.
• W2986351352 cites W1984148891 @default.
• W2986351352 cites W1996776294 @default.
• W2986351352 cites W2016787780 @default.
• W2986351352 cites W2035929291 @default.
• W2986351352 cites W2043583138 @default.
• W2986351352 cites W2048839541 @default.
• W2986351352 cites W2106922104 @default.
• W2986351352 cites W2112519660 @default.
• W2986351352 cites W2115017507 @default.
• W2986351352 cites W2122211082 @default.
• W2986351352 cites W2129669150 @default.
• W2986351352 cites W2135709083 @default.
• W2986351352 cites W2141838737 @default.
• W2986351352 cites W2144707045 @default.
• W2986351352 cites W2160719857 @default.
• W2986351352 cites W2185034389 @default.
• W2986351352 cites W2261318990 @default.
• W2986351352 cites W2339196082 @default.
• W2986351352 cites W2507955117 @default.
• W2986351352 cites W2521285559 @default.
• W2986351352 cites W2531444270 @default.
• W2986351352 cites W2560254258 @default.
• W2986351352 cites W2591661570 @default.
• W2986351352 cites W2734680224 @default.
• W2986351352 cites W2785610956 @default.
• W2986351352 cites W2946761884 @default.
• W2986351352 cites W4244328730 @default.
• W2986351352 doi "https://doi.org/10.1001/jamaneurol.2019.3812" @default.
• W2986351352 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6865783" @default.
• W2986351352 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31710340" @default.
• W2986351352 hasPublicationYear "2020" @default.
• W2986351352 type Work @default.
• W2986351352 sameAs 2986351352 @default.
• W2986351352 citedByCount "66" @default.
• W2986351352 countsByYear W29863513522020 @default.
• W2986351352 countsByYear W29863513522021 @default.
• W2986351352 countsByYear W29863513522022 @default.
• W2986351352 countsByYear W29863513522023 @default.
• W2986351352 crossrefType "journal-article" @default.
• W2986351352 hasAuthorship W2986351352A5000251461 @default.
• W2986351352 hasAuthorship W2986351352A5004309716 @default.
• W2986351352 hasAuthorship W2986351352A5010100808 @default.
• W2986351352 hasAuthorship W2986351352A5013396563 @default.
• W2986351352 hasAuthorship W2986351352A5013736647 @default.
• W2986351352 hasAuthorship W2986351352A5014895236 @default.
• W2986351352 hasAuthorship W2986351352A5019555711 @default.
• W2986351352 hasAuthorship W2986351352A5024865877 @default.
• W2986351352 hasAuthorship W2986351352A5025837253 @default.
• W2986351352 hasAuthorship W2986351352A5026319863 @default.
• W2986351352 hasAuthorship W2986351352A5026607111 @default.
• W2986351352 hasAuthorship W2986351352A5029927430 @default.
• W2986351352 hasAuthorship W2986351352A5037972521 @default.
• W2986351352 hasAuthorship W2986351352A5042845698 @default.
• W2986351352 hasAuthorship W2986351352A5046120768 @default.
• W2986351352 hasAuthorship W2986351352A5049403885 @default.
• W2986351352 hasAuthorship W2986351352A5052536571 @default.
• W2986351352 hasAuthorship W2986351352A5055043813 @default.
• W2986351352 hasAuthorship W2986351352A5056503861 @default.
• W2986351352 hasAuthorship W2986351352A5059104887 @default.
• W2986351352 hasAuthorship W2986351352A5060811086 @default.
• W2986351352 hasAuthorship W2986351352A5063637830 @default.
• W2986351352 hasAuthorship W2986351352A5072009949 @default.
• W2986351352 hasAuthorship W2986351352A5075757950 @default.
• W2986351352 hasAuthorship W2986351352A5090742144 @default.
• W2986351352 hasBestOaLocation W29863513521 @default.
• W2986351352 hasConcept C142724271 @default.

• next